ArticlePharmacoEconomics - open2021

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States.

Ash Bullement et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.